Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers
Authors:
- 1 June 2009
- journal article
- research article
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 34 (3) , 301-311
Abstract
Antifungal agent utility can be limited by safety and tolerability concerns. Posaconazole is an extended-spectrum triazole antifungal agent for the treatment and prophylaxis of invasive fungal infection. The aim was to analyse the overall safety profile of posaconazole in healthy volunteers. Safety data from all 18 clinical pharmacology single- and multiple-dose trials of posaconazole conducted in healthy volunteers plus 2 additional healthy subsets from other pharmacology trials were pooled and analysed. Four hundred and forty-nine healthy volunteers (354 men; 95 women) were enrolled. Three hundred and twenty-seven were white, and the mean age and weight of subjects were similar across all dosing groups. The population evaluated had no confounding factors of underlying disease or concomitant medications. Safety evaluations included spontaneously reported adverse events, clinical laboratory test results, electrocardiograms and vital sign measurements. A total of 448 subjects received posaconazole, 50-1200 mg/day administered as single or multiple doses for up to 14 days. Two hundred and seventeen subjects received >or=800 mg/day posaconazole, and 188 subjects received multiple doses of posaconazole at 800 mg/day. Two hundred and thirty-one subjects received <800 mg/day. Forty-eight subjects from three studies received placebo. The incidence of treatment-emergent adverse events reported with posaconazole was similar to that seen with placebo (57% vs. 63% respectively) and unrelated to dose. The most common treatment-related adverse events (posaconazole vs. placebo) were headache (17% vs. 13%), dry mouth (9% vs. 0%) and dizziness (6% vs. 2%). No clinically significant changes in vital signs or laboratory test parameters were observed, except for transient, mild to moderate elevations in liver function test results. Posaconazole also demonstrated minimal potential to prolong corrected QT interval. The safety profile analysis found posaconazole to be well tolerated, and results were similar across sex, age and race.Keywords
This publication has 25 references indexed in Scilit:
- Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host DiseaseNew England Journal of Medicine, 2007
- Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with NeutropeniaNew England Journal of Medicine, 2007
- Posaconazole as Salvage Treatment for Invasive Fusariosis in Patients with Underlying Hematologic Malignancy and Other ConditionsClinical Infectious Diseases, 2006
- A Multicenter Randomized Trial Evaluating Posaconazole versus Fluconazole for the Treatment of Oropharyngeal Candidiasis in Subjects with HIV/AIDSClinical Infectious Diseases, 2006
- Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 CasesClinical Infectious Diseases, 2006
- PosaconazoleDrugs, 2005
- Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infectionsInternational Journal Of Clinical Practice, 2004
- Drug-Induced Prolongation of the QT IntervalNew England Journal of Medicine, 2004
- Pharmacokinetics, Safety, and Tolerability of Oral Posaconazole Administered in Single and Multiple Doses in Healthy AdultsAntimicrobial Agents and Chemotherapy, 2003
- Adverse Events Associated with High-Dose Rifabutin in Macrolide-Containing Regimens for the Treatment of Mycobacterium avium Complex Lung DiseaseClinical Infectious Diseases, 1995